Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PSMA-directed Targeted Alpha Therapy With FPI-2265 (225Ac-PSMA-I&T) for the Treatment of Metastatic Castration-resISTant Prostate Cancer (TATCIST). A Phase II Clinical Trial.

NCT05219500 is registered in ClinicalTrials.gov with Fusion Pharmaceuticals Inc. as lead sponsor.

NCT NCT05219500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05219500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PSMA-directed Targeted Alpha Therapy With FPI-2265 (225Ac-PSMA-I&T) for the Treatment of Metastatic Castration-resISTant Prostate Cancer (TATCIST). A Phase II Clinical Trial.
Lead sponsor
Fusion Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 16, 2021
Completion date
July 31, 2026
Enrollment
115 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer